In 2020, the Angiogenesis Inhibitor Drug Class Will Account for Nearly Half of the Ovarian Cancer Drug Market

Avastin Will Become a Key Player as the First Targeted Therapy Approved for Ovarian Cancer and Will Garner Sales of $428 Million in 2020, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2020, the angiogenesis inhibitor drug class will account for nearly half of the ovarian cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Following the launch and uptake of each agent, combined sales of Roche/Genentech/Chugai’s Avastin and Amgen’s novel Tie2-targeted peptibody, AMG-386, will result in the angiogenesis inhibitor drug class accounting for 46 percent of the ovarian cancer market in 2020.

The findings from the Pharmacor topic entitled Ovarian Cancer reveal that Avastin, which is currently used off-label to treat the disease in some markets, will become a key player as the first targeted therapy to be approved for ovarian cancer, and its sales will reach $428 million in 2020. AMG-386, which is expected to launch for ovarian cancer in 2014, is not expected to take substantial patient share from the established Avastin and, as a result, will earn modest peak-year sales of $70 million in the world’s major pharmaceutical markets.

The findings also reveal that drug development for ovarian cancer is increasingly focusing on distinct characteristics of the disease. AstraZeneca’s polyadenosine 5’-diphosphoribose polymerase (PARP) inhibitor olaparib has demonstrated promising results in the treatment of DNA-repair-deficient tumors such as those with serous histology and tumors with BRCA-1 and BRCA-2 mutations.

“We forecast that olaparib will be the first PARP inhibitor to enter the ovarian cancer market and its sales will exceed $100 million in 2020,” said Decision Resources Analyst Amy Duval.

The Pharmacor Patient Flow Model for Ovarian Cancer finds that a modest decline in age-specific disease risk and projected improvements in recurrence-free survival will counter the increased disease risk due to aging and will limit growth of new drug-treatment opportunities for advanced ovarian cancer. The number of cases eligible for drug treatment of early-stage disease will be limited to 12 percent growth from 2010 to 2025.

“Based on historical trends in recurrence risk as well as an increasing percentage of early stage patients receiving adjuvant drug treatment, our patient flow model for ovarian cancer projects an annual reduction of 2 percent per year in recurrent cases and an improvement in survival for advanced disease from 2.5 years to 2.7 years by 2025,” said Decision Resources Senior Epidemiologist Donal Minihan.

About Pharmacor

Decision Resources’ Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Pharmacor Patient Flow Models

By utilizing our proprietary Pharmacor epidemiological data, Decision Resources now provides Pharmacor Patient Flow Models covering breast cancer, colorectal cancer, gastric cancer, malignant melanoma, non-small-cell lung cancer, ovarian cancer, prostate cancer and renal cell carcinoma. Using Pharmacor Patient Flow Models, users can build their own oncology patient flow model and/or validate the logic behind their own internal models. This interactive tool allows users to track changing disease and population dynamics over a 15-year annualized forecast, improve their modeling accuracy with clearly depicted methods and transparent assumptions and identify untapped market potential within lines of therapy. Pharmacor Patient Flow Models is available as an add-on product to the Pharmacor advisory service.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources
Christopher Comfort, 781-993-2597

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical